Cargando…
Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation
Modulation of the innate immune system is emerging as a promising therapeutic strategy against Alzheimer's disease (AD). However, determinants of a beneficial therapeutic effect are ill-understood. Thus, we investigated the potential of 18 kDa translocator protein positron-emission-tomography (...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419052/ https://www.ncbi.nlm.nih.gov/pubmed/34522221 http://dx.doi.org/10.7150/thno.64022 |
_version_ | 1783748679136444416 |
---|---|
author | Biechele, Gloria Blume, Tanja Deussing, Maximilian Zott, Benedikt Shi, Yuan Xiang, Xianyuan Franzmeier, Nicolai Kleinberger, Gernot Peters, Finn Ochs, Katharina Focke, Carola Sacher, Christian Wind, Karin Schmidt, Claudio Lindner, Simon Gildehaus, Franz-Josef Eckenweber, Florian Beyer, Leonie von Ungern-Sternberg, Barbara Bartenstein, Peter Baumann, Karlheinz Dorostkar, Mario M. Rominger, Axel Cumming, Paul Willem, Michael Adelsberger, Helmuth Herms, Jochen Brendel, Matthias |
author_facet | Biechele, Gloria Blume, Tanja Deussing, Maximilian Zott, Benedikt Shi, Yuan Xiang, Xianyuan Franzmeier, Nicolai Kleinberger, Gernot Peters, Finn Ochs, Katharina Focke, Carola Sacher, Christian Wind, Karin Schmidt, Claudio Lindner, Simon Gildehaus, Franz-Josef Eckenweber, Florian Beyer, Leonie von Ungern-Sternberg, Barbara Bartenstein, Peter Baumann, Karlheinz Dorostkar, Mario M. Rominger, Axel Cumming, Paul Willem, Michael Adelsberger, Helmuth Herms, Jochen Brendel, Matthias |
author_sort | Biechele, Gloria |
collection | PubMed |
description | Modulation of the innate immune system is emerging as a promising therapeutic strategy against Alzheimer's disease (AD). However, determinants of a beneficial therapeutic effect are ill-understood. Thus, we investigated the potential of 18 kDa translocator protein positron-emission-tomography (TSPO-PET) for assessment of microglial activation in mouse brain before and during chronic immunomodulation. Methods: Serial TSPO-PET was performed during five months of chronic microglia modulation by stimulation of the peroxisome proliferator-activated receptor (PPAR)-γ with pioglitazone in two different mouse models of AD (PS2APP, App(NL-G-F)). Using mixed statistical models on longitudinal TSPO-PET data, we tested for effects of therapy and sex on treatment response. We tested correlations of baseline with longitudinal measures of TSPO-PET, and correlations between PET results with spatial learning performance and β-amyloid accumulation of individual mice. Immunohistochemistry was used to determine the molecular source of the TSPO-PET signal. Results: Pioglitazone-treated female PS2APP and App(NL-G-F) mice showed attenuation of the longitudinal increases in TSPO-PET signal when compared to vehicle controls, whereas treated male App(NL-G-F) mice showed the opposite effect. Baseline TSPO-PET strongly predicted changes in microglial activation in treated mice (R = -0.874, p < 0.0001) but not in vehicle controls (R = -0.356, p = 0.081). Reduced TSPO-PET signal upon pharmacological treatment was associated with better spatial learning despite higher fibrillar β-amyloid accumulation. Immunohistochemistry confirmed activated microglia to be the source of the TSPO-PET signal (R = 0.952, p < 0.0001). Conclusion: TSPO-PET represents a sensitive biomarker for monitoring of immunomodulation and closely reflects activated microglia. Sex and pre-therapeutic assessment of baseline microglial activation predict individual immunomodulation effects and may serve for responder stratification. |
format | Online Article Text |
id | pubmed-8419052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-84190522021-09-13 Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation Biechele, Gloria Blume, Tanja Deussing, Maximilian Zott, Benedikt Shi, Yuan Xiang, Xianyuan Franzmeier, Nicolai Kleinberger, Gernot Peters, Finn Ochs, Katharina Focke, Carola Sacher, Christian Wind, Karin Schmidt, Claudio Lindner, Simon Gildehaus, Franz-Josef Eckenweber, Florian Beyer, Leonie von Ungern-Sternberg, Barbara Bartenstein, Peter Baumann, Karlheinz Dorostkar, Mario M. Rominger, Axel Cumming, Paul Willem, Michael Adelsberger, Helmuth Herms, Jochen Brendel, Matthias Theranostics Research Paper Modulation of the innate immune system is emerging as a promising therapeutic strategy against Alzheimer's disease (AD). However, determinants of a beneficial therapeutic effect are ill-understood. Thus, we investigated the potential of 18 kDa translocator protein positron-emission-tomography (TSPO-PET) for assessment of microglial activation in mouse brain before and during chronic immunomodulation. Methods: Serial TSPO-PET was performed during five months of chronic microglia modulation by stimulation of the peroxisome proliferator-activated receptor (PPAR)-γ with pioglitazone in two different mouse models of AD (PS2APP, App(NL-G-F)). Using mixed statistical models on longitudinal TSPO-PET data, we tested for effects of therapy and sex on treatment response. We tested correlations of baseline with longitudinal measures of TSPO-PET, and correlations between PET results with spatial learning performance and β-amyloid accumulation of individual mice. Immunohistochemistry was used to determine the molecular source of the TSPO-PET signal. Results: Pioglitazone-treated female PS2APP and App(NL-G-F) mice showed attenuation of the longitudinal increases in TSPO-PET signal when compared to vehicle controls, whereas treated male App(NL-G-F) mice showed the opposite effect. Baseline TSPO-PET strongly predicted changes in microglial activation in treated mice (R = -0.874, p < 0.0001) but not in vehicle controls (R = -0.356, p = 0.081). Reduced TSPO-PET signal upon pharmacological treatment was associated with better spatial learning despite higher fibrillar β-amyloid accumulation. Immunohistochemistry confirmed activated microglia to be the source of the TSPO-PET signal (R = 0.952, p < 0.0001). Conclusion: TSPO-PET represents a sensitive biomarker for monitoring of immunomodulation and closely reflects activated microglia. Sex and pre-therapeutic assessment of baseline microglial activation predict individual immunomodulation effects and may serve for responder stratification. Ivyspring International Publisher 2021-08-19 /pmc/articles/PMC8419052/ /pubmed/34522221 http://dx.doi.org/10.7150/thno.64022 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Biechele, Gloria Blume, Tanja Deussing, Maximilian Zott, Benedikt Shi, Yuan Xiang, Xianyuan Franzmeier, Nicolai Kleinberger, Gernot Peters, Finn Ochs, Katharina Focke, Carola Sacher, Christian Wind, Karin Schmidt, Claudio Lindner, Simon Gildehaus, Franz-Josef Eckenweber, Florian Beyer, Leonie von Ungern-Sternberg, Barbara Bartenstein, Peter Baumann, Karlheinz Dorostkar, Mario M. Rominger, Axel Cumming, Paul Willem, Michael Adelsberger, Helmuth Herms, Jochen Brendel, Matthias Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation |
title | Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation |
title_full | Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation |
title_fullStr | Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation |
title_full_unstemmed | Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation |
title_short | Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation |
title_sort | pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419052/ https://www.ncbi.nlm.nih.gov/pubmed/34522221 http://dx.doi.org/10.7150/thno.64022 |
work_keys_str_mv | AT biechelegloria pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT blumetanja pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT deussingmaximilian pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT zottbenedikt pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT shiyuan pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT xiangxianyuan pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT franzmeiernicolai pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT kleinbergergernot pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT petersfinn pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT ochskatharina pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT fockecarola pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT sacherchristian pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT windkarin pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT schmidtclaudio pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT lindnersimon pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT gildehausfranzjosef pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT eckenweberflorian pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT beyerleonie pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT vonungernsternbergbarbara pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT bartensteinpeter pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT baumannkarlheinz pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT dorostkarmariom pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT romingeraxel pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT cummingpaul pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT willemmichael pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT adelsbergerhelmuth pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT hermsjochen pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation AT brendelmatthias pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation |